Investigating Actinium-225 Radiochemistry: A Step Towards Next-Generation Radiotherapy
The U.S. Department of Energy (DoE) highlighted potential applications of Actinium-225 (225Ac) in treating prostate cancer in 2018, opening a new era of alpha emitter-based targeted therapy. Alpha particle emitter, 225Ac has high linear energy transfer that leads to lethal double stranded DNA breaks that can effectively kill tumor cells. Additionally, 225Ac has a short path length (< 100 µm) in tissues, which confines the off-target toxicity. Therefore, developing targeted radiotherapy with 225Ac and exploring its applications in hard-to-treat cancers is timely and innovative, and brings strong impact to patients suffering from untreatable tumors that cannot be completely removed by surgical resection and are resistant to frontline chemo- and immuno-therapies.
We propose to investigate the feasibility of targeted 225Ac radiotherapy in immune-evasive metastatic ovarian cancer via a highly collaborative multidisciplinary study that will design and systematically characterize novel 225Ac-labeled antibody-based probes and evaluate their anti-tumor efficacy in vitro and in vivo. This project aligns with University’s four strategic goals: 1) the proposed work will set important guidelines for future research on targeted alpha radiotherapy at the University of Utah as well as the scientific community; 2) students involved in this study will gain unique experience and skillset by conducting interdisciplinary research and publishing high-profile papers; 3) this work engages multidisciplinary research community including radiology, biotechnology, chemistry, and cancer therapy to build an inclusive team to eventually benefit clinical management of refractory cancers; 4) this work will contribute to the University’s long-term visibility. To achieve these goals, we have established a new cross-campus collaboration between the School of Medicine (Dr Sixiang Shi), College of Engineering (Dr Tara Mastren) and College of Pharmacy (Dr Shreya Goel).
School of Medicine
College of Pharmacy
College of Engineering
Civil And Environmental Engg
Project InfoFunded Project Amount
Actinium-225, Radiochemistry, Antibody, Cancer, Radiotherapy